<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274348</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01904-53</org_study_id>
    <nct_id>NCT04274348</nct_id>
  </id_info>
  <brief_title>Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum</brief_title>
  <acronym>STADEH</acronym>
  <official_title>Role of Staphylococci on Cytokine and T Cell Profiles in the Pathogenesis of Atopic Dermatitis and Eczema Herpeticum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies&#xD;
      have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD,&#xD;
      but the implication of bacterial virulence factors remains largely uncharacterized. Finally,&#xD;
      AD is often associated with herpes simplex skin infections. The aim of this project is to&#xD;
      investigate the role of staphylococcal toxins in the exacerbation and maintenance of atopic&#xD;
      skin inflammation and in the occurrence of infectious complications such as eczema&#xD;
      herpeticum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of S. aureus colonization level and characterization of bacterial virulence profile in AD lesions.</measure>
    <time_frame>2 hours (with consultation and sample)</time_frame>
    <description>Biological data obtained from lesional skin will be compared with those of healthy skin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the inflammatory profile of skin and blood during AD. Definition of the seric cytokine signature characteristic of AD. Characterization of the phenotype and function of the lymphocytic infiltrate T during AD.</measure>
    <time_frame>2 hours (with consultation and sample)</time_frame>
    <description>Biological data obtained from lesional skin will be compared with those of healthy skin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Staphylococcus Aureus</condition>
  <condition>Bacterial Toxins</condition>
  <condition>Immune Response</condition>
  <condition>Cytokines</condition>
  <condition>T Cells Subsets</condition>
  <arm_group>
    <arm_group_label>Skin biopsies and blood samples</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin biopsies and blood samples</intervention_name>
    <description>Two skin biopsies and 30 ml of blood will be collected.</description>
    <arm_group_label>Skin biopsies and blood samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate AD (SCORAD between 25 and 50) or severe AD (SCORAD&gt; 50)&#xD;
&#xD;
          -  Skin lesions in the forearms&#xD;
&#xD;
          -  Free subject, without neither guardianship, wardship nor subordination&#xD;
&#xD;
          -  Patient with Social Security&#xD;
&#xD;
          -  Informed and signed consent by the patient after clear and loyal information on the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 year-old&#xD;
&#xD;
          -  Patients with mild AD (SCORAD &lt; 25)&#xD;
&#xD;
          -  Patients without skin lesions in the forearms&#xD;
&#xD;
          -  Patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks&#xD;
&#xD;
          -  Patients under systemic treatment : Methotrexate, Ciclosporin, Mycophenolate Mofetil,&#xD;
             Azathioprine, general corticosteroids for less than 4 weeks&#xD;
&#xD;
          -  Patients under biological treatment : Dupilumab for less than 5 half-lives&#xD;
&#xD;
          -  Patient without Social Security&#xD;
&#xD;
          -  Pregnant and nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ewa HAINAUT, Dr</last_name>
    <phone>05 49 44 45 31</phone>
    <email>ewa.hainaut@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien SENESCHAL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa HAINAUT</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kaposi Varicelliform Eruption</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

